Arovella Therapeutics (ASX: ALA)

Last close As at 28/03/2024

0.03

0.00 (0.00%)

Market capitalisation

AUD26m

Arovella Therapeutics is a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system.

Latest Insights

View More

Healthcare | Flash note

Arovella Therapeutics — Strategic refocus on iNKT platform

Healthcare | Flash note

Arovella Therapeutics — Positive collaboration with ALA-101

Healthcare | Update

Arovella Therapeutics — Progressing on all fronts

Sector

Healthcare

Balance Sheet

Forecast net debt (A$m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (5.6) 36.0 (15.0)
Relative 0.6 39.5 (11.6)
52 week high/low A$0.0/A$0.0

Financials

Edison Investment Research is terminating coverage on Arovella Therapeutics. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2021A 0.3 (3.1) (3.4) (1.15) N/A N/A
2022A 0.3 (7.0) (7.4) (1.42) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free